z-logo
Premium
Synthesis and Pharmacological Evaluation of Novel Arginine Analogs as Potential Inhibitors of Acetylcholine‐Induced Relaxation in Rat Thoracic Aortic Rings
Author(s) -
Jain Manish,
Barthwal Manoj Kumar,
Haq Wahajul,
Katti Seturam B.,
Dikshit Madhu
Publication year - 2012
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/j.1747-0285.2011.01286.x
Subject(s) - acetylcholine , pharmacology , arginine , chemistry , medicine , biochemistry , amino acid
It is widely appreciated that the vascular endothelium is capable of modulating vascular smooth muscle tone suiting it well for its role as an important regulator of a number of diverse biological processes. Endothelial dysfunction is an early manifestation of atherothrombosis and a consequence of the established disease. Although several arginine derivatives alkylated at one of the guanidino nitrogen were found to inhibit vasorelaxation induced by acetylcholine, activity of the corresponding arginine esters is not reported. The present work was therefore designed to synthesize and evaluate series of novel arginine derivatives to obtain further insight into structure–activity relationship in this series of compounds. Present study involves assessment of activity of these novel compounds on the vascular tone of rat thoracic aorta in comparison with l ‐arginine analog, that is, l ‐nitro‐arginine methyl ester ( l ‐NAME). Results from the present study showed that full reversal of phenylephrine‐mediated contraction was achieved by cumulative applications of acetylcholine (3 n m –300 μ m ), which were abolished when the aortic rings were pretreated with l ‐NAME (300 μ m ). Results from the present study demonstrated that these novel arginine derivatives cause significant yet reversible reduction in acetylcholine‐mediated relaxation, similar to that of l ‐NAME.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here